tAnGo: A randomised phase III trial of gemcitabine in paclitaxel- containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: A prospective pulmonary, cardiac and hepatic function evaluation

British Journal of Cancer

Volumn 99, Issue 4, 2008, Pages 597-603

  Wardley, A M ^a   Hiller, L ^b   Howard, H C ^c   Dunn, J A ^b   Bowman, A ^d   Coleman, R E ^e   Fernando, I N ^f   Ritchie, D M ^g   Earl, H M ^h   Poole, C J ^c  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Breast cancer; Pulmonary; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; GEMCITABINE; PACLITAXEL;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DYSPNEA; ECHOCARDIOGRAPHY; ENZYME DEFECT; FATIGUE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TRACT TOXICITY; HEART FUNCTION; HUMAN; INFECTION; LIVER FUNCTION; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MYALGIA; NEUROPATHY; NEUTROPENIA; ORAL TOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TIME; TOXICITY; TRANSAMINITIS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HEART; HEART FUNCTION TESTS; HUMANS; LIVER; LIVER FUNCTION TESTS; LUNG; PACLITAXEL; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SURVIVAL RATE;

EID: 49549089514     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604538     Document Type: Article

References (26)

1. Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K (1999) Prolonged infusion of gemcitabine in stage I. V. breast cancer: a phase I study. Anticancer Drugs 10: 525- 531
2. Blackstein M, Vogel CL, Ambinder R, Cowan J, Pearce P, Iglesias J (1997) Phase II study of gemcitabine in patient with metastatic breast cancer. Eur J Cancer 33(Suppl. 8): S149
3. Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P (2004) Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 22(9): 1614-1620
4. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris Al (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13(11): 2731-2736
5. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8(2): 119- 127
6. Colomer R, Llombart A, Lluch A, Ojeda B, Barnadas A, Caranana V, Fernandez Y, De Paz L, Guillem V, Alonso S (2000) Paclitaxel/ gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol 27(1 Suppl 2): 20-24
7. Dimopoulou I, Galani H, Dafni U, Samakovli A, Roussos C, Dimopoulos MA (2002) A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 94(2): 452-458
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrance and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-1717
9. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial. J Bone Miner Res 21(8): 1215-1223
10. Fossella FV, Lippman SM, Shin DM, Tarassoff P, CalayagJung M, PerezSoler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK (1997) Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15(1): 310-316
11. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B (2002) Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 25(1): 96-100
12. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6): 976-983
13. Jeter MD, Janne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia R (2002) Gemcitabine-induced radiation recall. Int J Radiation Oncol Biol Phys 53(2): 394-400
14. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJA, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17: 2190-2197
15. Levine MN, Pritchard KL, Bramwell VHC, Shepherd LE, Tu DS, Paul N (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23(22): 5166-5170
16. Maas KW, van der Lee I, Bolt K, Zanen P, Lammers JWJ, Schramel FMNH (2003) Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41(3): 345-351
17. Mamounas EP, Bryant J, Leinbersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16): 3686-3696
18. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N (2003) Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 22(4)
19. McGinn CJ, Shewach DS, Lawrence TS (1996) Radiosensitizing nucleosides. J Natl Cancer Inst 88(17): 1193-1203
20. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RCF, Twelves CJ (2006a) Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. New Engl J Med 355(18): 1851- 1862
21. Poole CJ, Perren T, Gawande S, Ridderheim M, Cook J, Jenkins A, Roychowdhury D (2006b) Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer. Int J Gynecol Cancer 16(2): 507-514
22. Quanjer PH (ed) (1993) ERS 1993 update. Eur Respir J 6: S16
23. Sanchez P, Medina MB, Mohedano N, Jaen A, Porras I, Gonzalez E, Fernandez M, Lozano A (1998) Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Ann Oncol 9(Suppl 4): 77P
24. Sara S, King E, Unger M, Langer C (2000) Retrospective analysis of gemcitabine induced pulmonary toxicity: critical management issues. Proc Am Soc Clin Oncol 19: 2402
25. Spielmann M, Kalla S, LlombartCussac A, Espie M, Namer M, Ferrero JM, Cuvier C, Fumoleau P, Ponzio A, Kayitalire L, Pouillart P (1997) Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens. Eur J Cancer 33(Suppl. 8): S149
26. Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, Margaritora S, Cesario A, D'Angelillo RM, Gualano G, Ramella S, Galetta D, Cellini N (2002) Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20: 804-810